Research programme: Rho kinase inhibitors - Galapagos

Drug Profile

Research programme: Rho kinase inhibitors - Galapagos

Alternative Names: BF 66851; BF 66852; BF 66853; Rho kinase inhibitors research programme - BioFocus; ROK inhibitors - BioFocus

Latest Information Update: 13 Apr 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galapagos NV
  • Class
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders

Most Recent Events

  • 13 Apr 2007 Discontinued - Preclinical for Cardiovascular disorders in United Kingdom (unspecified route)
  • 04 Nov 2005 BioFocus has been acquired and merged into Galapagos NV
  • 01 Sep 2004 This programme is available for licensing (http://www.biofocus.com/)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top